AR051946A1 - Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina - Google Patents
Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolinaInfo
- Publication number
- AR051946A1 AR051946A1 ARP050104612A ARP050104612A AR051946A1 AR 051946 A1 AR051946 A1 AR 051946A1 AR P050104612 A ARP050104612 A AR P050104612A AR P050104612 A ARP050104612 A AR P050104612A AR 051946 A1 AR051946 A1 AR 051946A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- weight
- component
- alkyl
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones de dosificacion solidas de derivados de [1,4]diazepina[6,7,1-ij]quinolina y procedimientos para su fabricacion. En algunas modalidades particulares nuevas formulaciones de un agente antipsicotico y antiobesidad clorhidrato (9aR, 12aS)- 4,5,6,7,9,9a,10,11,12,12a-decahidrociclopental[c][1,4]diazepina[6,7,1-ij]quinolina (compuesto A HCl). Forma de dosificacion unitaria. Reivindicacion 1: Una composicion farmacéutica, caracterizada porque comprende: a) una cantidad farmacéuticamente efectiva de un agente farmacologicamente activo que comprende desde alrededor de un 10% hasta alrededor de un 80% en peso de la composicion farmacéutica; b) un componente de relleno que comprende desde alrededor de un 10% hasta alrededor de un 80% en peso de la composicion farmacéutica; c) un componente opcional de recubrimiento y sellado que comprende desde alrededor de un 0,01% hasta alrededor de un 5% en peso de la composicion farmacéutica; d) un componente de recubrimiento entérico que comprende desde alrededor de un 0,01% hasta alrededor de un 20% en peso de la composicion farmacéutica; e) un componente deslizante opcional que comprende desde alrededor de un 0,01% hasta alrededor de un 20% en peso de la composicion farmacéutica; f) un componente plastificante adicional que comprende desde alrededor de un 0,01% hasta alrededor de un 3% en peso de la composicion farmacéutica; g) un componente neutralizador adicional que comprende desde alrededor de un 0,01% hasta alrededor de un 1,5% en peso de la composicion farmacéutica; h) un componente tensioactivo adicional que comprende desde alrededor de un 0,001% hasta alrededor de un 1,0% en peso de la composicion farmacéutica; i) un componente lubricante adicional que comprende desde alrededor de un 0,01% hasta alrededor de un 5,0% en peso de la composicion farmacéutica; en donde el agente farmacéutico activo tiene la formula (1) en donde: R1 es H, alquilo C1-6, alcanoilo C2-6, o carboarilalcoxi C7-11; R2 y R3 son cada uno, independientemente, H, hidroxi, alquilo C1-6, alcoxi C1-6, halogeno, carboxamida, carboalcoxi C2-6, perfluoroalquilo C1-6, ciano, alcanosulfonamida C1-8, alcanosulfonilo C1-8, alquilamido C1-8, amino, alquilamino C1-8, dialquilamino de 1-8 átomos de C por porcion de alquilo, perfluoroalcoxi C1-6, alcanoiloxi C2-6, alcanoilo C2-6, aroilo C6-8, arilo de 5-7 átomos de C, un grupo alquilarilo C6-13 que tiene de 5-7 átomos de C en la porcion arilo, un grupo heteroarilo de 5 a 7 miembros, o un grupo alquilheteroarilo de 6 a 13 miembros que tiene de 5 a 7 miembros en la porcion heteroarilo, en donde cualquiera de los sustituyentes R2 o R3 que tiene una porcion arilo o heteroarilo puede ser sustituido opcionalmente en la porcion arilo o heteroarilo con 1 a 3 sustituyentes independientemente seleccionados a partir de un átomo halogeno, un grupo alquilo C1-6, o un grupo alcoxi C1-6; R4 y R5 son, independientemente, H o alquilo C1-6, o R4 y R5, tomados conjuntamente con los carbonos a los cuales están unidos, forman una porcion cíclica seleccionada a partir de un cicloalcano C4-8, cicloalqueno C4-8, alcano bicíclico unido por puente de 5 a 10 átomos de C, alqueno bicíclico unido por puente de 5 a 10 átomos de C, pirano o tiopirano en donde el átomo de S se oxida, opcionalmente, para transformarse en sulfoxido o sulfono, en donde la porcion cíclica formada por R4 y R5 puede ser substituida opcionalmente con 1 a 3 sustituyentes independientemente seleccionados a partir de un átomo halogeno, un grupo alquilo C1-6 o un grupo alcoxi C1-6; R6 y R7 son cada uno, independientemente, H o alquilo C1-6, n es 1 o 2; y una línea punteada representa un doble enlace opcional; o una sal farmacéuticamente aceptable de los mismos. Reivindicacion 53: El producto, caracterizado porque se obtiene del procedimiento de acuerdo con cualquiera de la reivindicaciones 41 a 52. Reivindicacion 82: La composicion farmacéutica de acuerdo con la reivindicacion 11, caracterizada porque comprende, además, un componente de liberacion sostenida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62528004P | 2004-11-05 | 2004-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051946A1 true AR051946A1 (es) | 2007-02-21 |
Family
ID=35841773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104612A AR051946A1 (es) | 2004-11-05 | 2005-11-01 | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
Country Status (19)
Country | Link |
---|---|
US (1) | US20060110451A1 (es) |
EP (1) | EP1807088A1 (es) |
JP (1) | JP2008519057A (es) |
KR (1) | KR20070084010A (es) |
CN (1) | CN101094675A (es) |
AR (1) | AR051946A1 (es) |
AU (1) | AU2005304758A1 (es) |
BR (1) | BRPI0517060A (es) |
CA (1) | CA2586124A1 (es) |
GT (1) | GT200500318A (es) |
IL (1) | IL182800A0 (es) |
MX (1) | MX2007005478A (es) |
NO (1) | NO20072169L (es) |
PE (1) | PE20060944A1 (es) |
RU (1) | RU2007114079A (es) |
SV (1) | SV2006002293A (es) |
TW (1) | TW200630100A (es) |
WO (1) | WO2006052887A1 (es) |
ZA (1) | ZA200703623B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500317A (es) * | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
TW200806297A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | Methods for treating cognitive and other disorders |
EP1998781A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
PE20080010A1 (es) * | 2006-03-24 | 2008-03-10 | Wyeth Corp | Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden |
EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
AU2015330937B2 (en) * | 2014-10-08 | 2021-07-15 | Theriva Biologics, Inc. | Beta-lactamase formulations and uses thereof |
WO2016196440A1 (en) | 2015-06-01 | 2016-12-08 | Xeno Biosciences Inc. | Methods and compositions to modulate the gut microbiota and to manage weight |
CN105920017B (zh) * | 2016-06-08 | 2018-06-05 | 广州嘉德乐生化科技有限公司 | 一种治疗单纯性肥胖症的药物组合物及其用途 |
CN110520111B (zh) * | 2016-11-30 | 2023-12-19 | 塞诺生物科学股份有限公司 | 用以管理体重和调节肠道微生物群的药物制剂和方法 |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
CN111743976A (zh) * | 2020-07-03 | 2020-10-09 | 广西医科大学 | 一种二氧化硅气凝胶在制备治疗骨关节炎药物中的应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3158619A (en) * | 1962-06-14 | 1964-11-24 | Searle & Co | Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives |
US3235564A (en) * | 1964-03-27 | 1966-02-15 | Searle & Co | Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives |
US3296252A (en) * | 1964-04-02 | 1967-01-03 | Sandoz Ag | Tetracyclic diazepinone compounds |
US3335134A (en) * | 1964-04-02 | 1967-08-08 | Sandoz Ag | Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones |
GB1120461A (en) * | 1964-07-06 | 1968-07-17 | Manuf Prod Pharma | Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide |
US3417101A (en) * | 1964-11-09 | 1968-12-17 | American Home Prod | Fused ring compounds |
US3329676A (en) * | 1964-11-09 | 1967-07-04 | American Home Prod | Fused 1, 4-diazepine ring systems |
US3714149A (en) * | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
US3914250A (en) * | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US4880814A (en) * | 1987-11-13 | 1989-11-14 | Abbott Laboratories | 7-cycloalkyl naphthyridines |
GB8812636D0 (en) * | 1988-05-27 | 1988-06-29 | Glaxo Group Ltd | Chemical compounds |
US4997831A (en) * | 1988-09-01 | 1991-03-05 | Glaxo Group Limited | Lactam derivatives |
CA2195697A1 (en) * | 1996-02-02 | 1997-08-03 | Masahumi Kitano | Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof |
US6380166B1 (en) * | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
US6761904B2 (en) * | 2000-03-31 | 2004-07-13 | Nycomed Austria Gmbh | Pharmaceutical kit comprising midodrine as active drug substance |
US6759405B2 (en) * | 2000-11-03 | 2004-07-06 | Wyeth | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
AR031201A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | /1,4/diazepino/6,7,1-jk/carbazoles y derivados |
US6784172B2 (en) * | 2000-11-03 | 2004-08-31 | Wyeth | Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
AR031195A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol |
US6858604B2 (en) * | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
AR031198A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol |
AR031202A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados |
US7141563B2 (en) * | 2000-11-03 | 2006-11-28 | Wyeth | Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives |
PL366233A1 (en) * | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
JP2005501092A (ja) * | 2001-08-06 | 2005-01-13 | ファルマシア・アンド・アップジョン・カンパニー | 治療上有用な四環リガンド |
TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
TW200307682A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
AU2003303210A1 (en) * | 2002-12-19 | 2004-07-14 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
WO2004067039A1 (en) * | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
TW200806297A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | Methods for treating cognitive and other disorders |
-
2005
- 2005-11-01 AR ARP050104612A patent/AR051946A1/es unknown
- 2005-11-03 TW TW094138588A patent/TW200630100A/zh unknown
- 2005-11-03 PE PE2005001293A patent/PE20060944A1/es not_active Application Discontinuation
- 2005-11-04 GT GT200500318A patent/GT200500318A/es unknown
- 2005-11-04 KR KR1020077010290A patent/KR20070084010A/ko not_active Application Discontinuation
- 2005-11-04 WO PCT/US2005/040290 patent/WO2006052887A1/en active Application Filing
- 2005-11-04 US US11/267,605 patent/US20060110451A1/en not_active Abandoned
- 2005-11-04 SV SV2005002293A patent/SV2006002293A/es unknown
- 2005-11-04 AU AU2005304758A patent/AU2005304758A1/en not_active Abandoned
- 2005-11-04 JP JP2007540135A patent/JP2008519057A/ja active Pending
- 2005-11-04 CN CNA2005800457406A patent/CN101094675A/zh not_active Withdrawn
- 2005-11-04 RU RU2007114079/15A patent/RU2007114079A/ru not_active Application Discontinuation
- 2005-11-04 CA CA002586124A patent/CA2586124A1/en not_active Abandoned
- 2005-11-04 MX MX2007005478A patent/MX2007005478A/es unknown
- 2005-11-04 EP EP05824164A patent/EP1807088A1/en not_active Withdrawn
- 2005-11-04 BR BRPI0517060-5A patent/BRPI0517060A/pt not_active IP Right Cessation
-
2007
- 2007-04-26 NO NO20072169A patent/NO20072169L/no not_active Application Discontinuation
- 2007-04-26 IL IL182800A patent/IL182800A0/en unknown
- 2007-05-04 ZA ZA200703623A patent/ZA200703623B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL182800A0 (en) | 2007-09-20 |
CN101094675A (zh) | 2007-12-26 |
KR20070084010A (ko) | 2007-08-24 |
ZA200703623B (en) | 2009-10-28 |
MX2007005478A (es) | 2007-05-24 |
GT200500318A (es) | 2006-06-13 |
EP1807088A1 (en) | 2007-07-18 |
CA2586124A1 (en) | 2006-05-18 |
TW200630100A (en) | 2006-09-01 |
NO20072169L (no) | 2007-07-24 |
RU2007114079A (ru) | 2008-12-10 |
JP2008519057A (ja) | 2008-06-05 |
US20060110451A1 (en) | 2006-05-25 |
BRPI0517060A (pt) | 2008-09-30 |
AU2005304758A1 (en) | 2006-05-18 |
SV2006002293A (es) | 2006-10-13 |
WO2006052887A1 (en) | 2006-05-18 |
PE20060944A1 (es) | 2006-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051946A1 (es) | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
CO5570668A2 (es) | Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen | |
AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
HRP20090388T1 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
AR060220A1 (es) | Compuestos heterociclicos de 5 o 6 miembros, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas con la dgat1. | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
CY1110261T1 (el) | Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα | |
AR049284A1 (es) | Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
AR078507A1 (es) | Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion | |
AR063680A1 (es) | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. | |
AR050433A1 (es) | Derivados piperidilo de quinazolina e isoquinolina | |
PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
AR045938A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
AR035733A1 (es) | Compuestos heterociclicos terapeuticos, uso de dichos compuestos para la preparacion de medicamentos, compuestos relacionados y procedimientos para preparar estos compuestos relacionados | |
HRP20110005T1 (hr) | Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva | |
AR051089A1 (es) | Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas | |
AR049186A1 (es) | Derivados de oxazol como moduladores de ppar | |
AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
AR057576A1 (es) | Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor | |
RU2008129363A (ru) | Новые ациклические, замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний | |
PE20091182A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |